(Approval lapsed) CELESTONE CHRONODOSE betamethasone (as acetate and disodium phosphate) 5.7mg/1mL suspension for injection (Netherlands)

Celestone Chronodose is indicated in the treatment of both severe and moderate conditions, in acute and chronic self-limiting diseases responsive to systemic corticosteroid therapy, especially in patients for whom treatment with oral corticosteroid medication is not feasible.

Representative conditions:

• Rheumatic disorders - Rheumatoid arthritis, acute and subacute bursitis, epicondylitis, acute non-specific tenosynovitis, myositis, fibrositis, tendinitis, psoriatic arthritis.
• Collagen diseases - Systemic lupus erythematosus, scleroderma, dermatomyositis.
• Allergic states - Status asthmaticus, chronic bronchial asthma, seasonal or perennial allergic rhinitis, severe allergic bronchitis, contact dermatitis, atopic dermatitis, hypersensitivity reactions to drug and insect bites.
• Dermatological conditions - Localised, hypertrophic, infiltrated lesions of lichen planus, psoriatic plaques, granuloma annulare and lichen simplex chronicus (neurodermatitis), keloids, discoid lupus erythematosus, necrobiosis lipoidica diabeticorum, alopecia areata.
• Antepartum use in the prevention of respiratory distress syndrome in premature infants - When it is deemed necessary to induce labour prior to the thirty-second week of gestation or when premature birth before the thirty-second week of gestation becomes inevitable because of obstetric complication.

Celestone Chronodose Injection should also be considered for prophylactic treatment if the fetus is known to have a low lecithin/sphingomyelin ratio (or decreased foam stability test on amniotic fluid).